Streetbeat News

PTIX

Protagenic Therapeutics, Inc.

https://www.protagenic.com

Industry

Biotechnology

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Protagenic Therapeutics has resolved the Nasdaq deficiency notice it previously received, ensuring its continued listing on the exchange. This resolution may positively impact investor confidence and the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:43 pm

In Tuesday's intraday session, health care stocks saw significant movements. Sunshine Biopharma, Ocean Biomedical, Apogee Therapeutics, BeyondSpring, CareMax, and Protagenic Therapeutics experienced notable gains. Conversely, Quoin Pharmaceuticals, Ekso Bionics Holdings, Lipella Pharmaceuticals, Kineta, Eyenovia, and Semler Scientific faced declines. The movements were attributed to various factors including company earnings reports.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 5:33 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Shattuck Labs (STTK) saw a 93.8% increase, while Reshape Lifesciences (RSLS) rose by 89.48%. C4 Therapeutics (CCCC) and Avalo Therapeutics (AVTX) also saw substantial gains. Conversely, OneMedNet (ONMD) and Processa Pharma (PCSA) were among the stocks that declined, with drops of 21.7% and 19.84%, respectively.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 5:31 pm

Protagonist Therapeutics, Inc. presented two-year follow-up data from the Phase 2 REVIVE study of rusfertide at the ASH Annual Meeting. Rusfertide is a hepcidin mimetic with potential in treating polycythemia vera and other diseases. The presentations are available on the company's website.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 12:34 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Inovio Pharmaceuticals (INO), NanoString Technologies (NSTG), Scinai Immunotherapeutics (SCNI), Cyclerion Therapeutics (CYCN), Carmell Therapeutics (CTCX), and Vicarious Surgical (RBOT). Losers included Akero Therapeutics (AKRO), Athersys (ATHX), 89bio (ETNB), Ventyx Biosciences (VTYX), Protagenic Therapeutics (PTIX), and Nuwellis (NUWE).

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 5:31 pm

On Tuesday, 132 companies hit new 52-week lows. Among them, Corning (NYSE:GLW) was the largest in terms of market cap, while Wheeler Real Estate IT (NASDAQ:WHLR) was the smallest. Fortress Biotech (NASDAQ:FBIO) saw the largest move with shares plummeting 1350.03%, while Insulet (NASDAQ:PODD) made the biggest bounce back, moving up 0.0% shortly after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 5:09 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Vivos Therapeutics (VVOS), Nuvalent (NUVL), Histogen (HSTO), MiNK Therapeutics (INKT), Brainstorm Cell (BCLI), and Gritstone Bio (GRTS) saw their shares rise, with VVOS leading the gainers with a 105.4% increase. On the other hand, Inhibikase Therapeutics (IKT), Protagenic Therapeutics (PTIX), Standard BioTools (LAB), Nuwellis (NUWE), Lipella Pharmaceuticals (LIPO), and MSP Recovery (LIFW) saw their shares fall, with IKT leading the losers with a 33.2% decrease.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 5:31 pm

Protagenic Therapeutics has initiated a Phase I/IIa clinical trial for PT00114, a synthetic version of the naturally occurring brain peptide TCAP. The trial aims to evaluate the therapeutic potential of PT00114 in treating neuro-psychiatric conditions, including depression, anxiety, and PTSD. The study will recruit 56 subjects and will be managed by Axiom Real-Time Metrics.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.